<DOC>
	<DOCNO>NCT01215786</DOCNO>
	<brief_summary>This exploratory study evaluate safety pharmacodynamics 3 dos AGN-207281 base ongoing review data study period compare timolol ophthalmic solution placebo patient ocular hypertension primary open-angle glaucoma .</brief_summary>
	<brief_title>Safety Pharmacodynamics Study AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution Placebo Patients With Ocular Hypertension Primary Open-Angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Ocular hypertension primary openangle glaucoma eye Requires IOPlowering therapy eye Visual acuity score 20/100 good eye Experienced significant weight change ( 10 pound ) within 60 day History alcohol drug addiction History migraine frequent headache Anticipated wear contact lens study Required chronic use ocular medication study Eye surgery within 6 month Use systemic beta blocker ( eg , atenolol , propranolol ) within 2 month Use oral , intramuscular , intravenous corticosteroid within 21 day Use ophthalmic corticosteroid within 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>